BUZZ-Aurinia Pharmaceuticals: Canaccord starts with "buy"
** Drug developer's shares up 11 pct at $3.24
** Canaccord Genuity analysts started coverage of stock with "buy" rating and $10 price target
** Analysts believe Aurinia's drug for inflammatory disease Lupus could peak at $630 million in the United States, if approved
** Company currently running mid-stage trials on drug
** Stock has fallen more than 12 pct in last six months
© Thomson Reuters 2017 All rights reserved.